Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function | MicrobiomeTrials
Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-01-30Est. Completion: 2026-04-20
Enrollment target: 16 participants
Locations
Orlando Clinical Research Center, Orlando, Florida, United States